References
Slovis TL, Bernstein J, Gruskin A (1993) Hyperechoic kidneys in the newborn and young infant. Pediatr Nephrol 7:294–302
Mercato-Deane MG, Beeson JE, John SD (2002) US of renal insufficiency in neonates. Radiographics 22:1429–1438
Young BY, Veson E, Perlmutter S, Smith T (2004) Autosomal recessive polycystic kidney disease. eMedicine (www.emedicine.com/radio/topic69.htm)
Lanning P, Uhari M, Kouvalainen K, Lanning M (1989) Ultrasonic features of the congenital nephritic syndrome of the Finnish type. Acta Paediatr Scand 78:717–720
Haffner D, Wühl E, Zieger B, Grulich-Henn J, Mehls O, Schaefer F (1996) Bilateral renal venous thrombosis in a neonate associated with resistance to activated protein C. Pediatr Nephrol 10:737–739
Howlett DC, Greenwood KL, Jarosz JM, MacDonald LM, Saunders AJS (1997) The incidence of transient renal medullary hyperechogenicity in neonatal ultrasound examination. Br J Radiol 70:140–143
Lip GYH, Churchill D, Beevers M, Auckett A, Beevers DG (1997) Angiotensin-converting-enzyme inhibitors in early pregnancy. Lancet 350:1446–1447
Pryde PG, Sedman AB, Nugent CE, Barr M (1993) Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol 3:1575–1582
Barr M (1994) Teratogen update: Angiotensin-converting enzyme inhibitors. Teratology 50:399–409
Burrows RF, Burrows EA (1998) Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy. Aust N Z J Obstet Gynaecol 38:306–311
Shotan A, Widerhorn J, Hurst A (1994) Risks of angiotensin-converting enzyme inhibition during pregnancy: Experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 96:451–456
Magee LA (2001) Treating hypertension in women of child-bearing age and during pregnancy. Drug Saf 24:457–474
Hilgers KF, Norwood VP, Gomez RA (1997) Angiotensin’s role in renal development. Semin Nephrol 17:492–501
Lambot MA, Vermeylen D, Noel JC (2001) Angiotensin-II-receptor inhibitors in pregnancy. Lancet 357:1619–1620
Martinovic J, Benachi A, Laurent N, Daikha-Dahmane F, Gubler MC (2001) Fetal toxic effects and angiotensin-II-receptor antagonists. Lancet 358:241–242
Saji H, Yamanaka M, Hagiwara A, Ijiri R (2001) Losartan and fetal toxic effects. Lancet 357:363
Düker G, Bökenkamp A, Garbe W, Lentze MJ (2002) Lorsartan-Fetopathie—eine Kasuistik. Nieren-Hochdruckkrankh 31:67–68
Briggs GG, Nageotte MP(2001) Fatal fetal outcome with the combined use of valsartan and atenolol. Ann Pharmacother 35:859–861
Pietrement C, Malot L, Santerne B, Roussel B, Motte J, Morville P (2003) Neonatal acute renal failure to maternal exposure to telmisartan, angiotensin II receptor antagonist. J Perinatol 23:254–255
Hinsberger A, Wingen AM, Hoyer PF (2001) Angiotensin-II-receptor inhibitors in pregnancy. Lancet 357:1620
Author information
Authors and Affiliations
Corresponding author
Additional information
This refers to the article that can be found at http://dx.doi.org/10.1007/s00467-005-1937-2
Rights and permissions
About this article
Cite this article
Bald, M., Holder, M., Zieger, M. et al. Increased renal echogenicity in a preterm neonate: Answer. Pediatr Nephrol 20, 1666–1668 (2005). https://doi.org/10.1007/s00467-005-1938-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-005-1938-1